Literature DB >> 28282291

Higher serum caspase-cleaved cytokeratin-18 levels during the first week of sepsis diagnosis in non-survivor patients.

Leonardo Lorente1, María M Martín1, Antonia Pérez-Cejas1, Raquel Ortiz López1, José Ferreres1, Jordi Solé-Violán1, Lorenzo Labarta1, César Díaz1, Salomé Palmero1, Manuel Buitrago1, Alejandro Jiménez1, Juan M Borreguero-León1.   

Abstract

BACKGROUND: Caspase-cleaved cytokeratin (CCCK)-18 is a protein released into the blood during apoptosis. Higher circulating CCCK-18 concentrations have been found in non-survivor than in survivor septic patients at moment of sepsis diagnosis. The following questions arise now: (1) How are serum CCCK-18 levels during the first week of sepsis? (2) Is there an association between sepsis severity and mortality and serum CCCK-18 levels during the first week? The aims of this study were to answer these questions.
METHODS: Multicenter study with 321 severe septic patients from eight Spanish intensive care units. We determined serum concentration of CCCK-18, tumor necrosis factor (TNF)-α, and interleukin (IL)-10 during the first week. Our end-point study was 30-day mortality.
RESULTS: Non-survivor (n=108) compared to survivor patients (n=213) showed higher serum CCCK-18 levels at days 1, 4 and 8 (p<0.001). ROC curve analyses showed that serum CCCK-18 levels at days 1 (AUC=0.77; 95% CI=0.72-0.82), 4 (AUC=0.81; 95% CI=0.76-0.85) and 8 (AUC=0.83; 95% CI=0.78-0.88) could predict mortality at 30 days (p<0.001). Logistic regression analyses showed that serum CCCK-18 levels at days 1 (OR=4.367; 95% CI=2.491-7.659), 4 (OR=10.137; 95% CI=4.741-21.678) and 8 (OR=8.781; 95% CI=3.626-21.268) were associated with 30-day mortality (p<0.001). We found a positive correlation between CCCK-18, SOFA, and lactic acid at days 1, 4 and 8.
CONCLUSIONS: Non-survivor septic patients showed persistently during the first week higher serum CCCK-18 levels than survivor patients, and there is an association between sepsis severity and mortality and serum CCCK-18 levels during the first week.

Entities:  

Keywords:  caspase-cleaved cytokeratin (CCCK)-18; mortality; outcome; sepsis

Mesh:

Substances:

Year:  2017        PMID: 28282291     DOI: 10.1515/cclm-2016-1034

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Sustained high serum caspase-3 concentrations and mortality in septic patients.

Authors:  L Lorente; M M Martín; A Pérez-Cejas; A F González-Rivero; R O López; J Ferreres; J Solé-Violán; L Labarta; C Díaz; S Palmero; A Jiménez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-08       Impact factor: 3.267

2.  Sustained Low Serum Substance P Levels in Non-Surviving Septic Patients.

Authors:  Leonardo Lorente; María M Martín; Antonia Pérez-Cejas; José Ferreres; Jordi Solé-Violán; Lorenzo Labarta; César Díaz; Alejandro Jiménez
Journal:  Int J Mol Sci       Date:  2017-07-15       Impact factor: 5.923

3.  High serum levels of caspase-cleaved cytokeratin-18 are associated with malignant middle cerebral artery infarction patient mortality.

Authors:  Leonardo Lorente; María M Martín; Antonia Pérez-Cejas; Luis Ramos; Mónica Argueso; Jordi Solé-Violán; Juan J Cáceres; Alejandro Jiménez; Victor García-Marín
Journal:  BMC Neurol       Date:  2018-03-24       Impact factor: 2.474

4.  Association between serum levels of caspase-cleaved cytokeratin-18 and early mortality in patients with severe spontaneous intracerebral hemorrhage.

Authors:  Leonardo Lorente; María M Martín; Antonia Pérez-Cejas; Luis Ramos; Mónica Argueso; Jordi Solé-Violán; Juan J Cáceres; Alejandro Jiménez; Victor García-Marín
Journal:  BMC Neurosci       Date:  2018-04-16       Impact factor: 3.288

5.  Survivin and caspases serum protein levels and survivin variants mRNA expression in sepsis.

Authors:  Marianna Miliaraki; Panagiotis Briassoulis; Stavroula Ilia; Aikaterini Polonifi; Marina Mantzourani; Efrossini Briassouli; Konstantinos Vardas; Serafim Nanas; Aikaterini Pistiki; Maria Theodorakopoulou; Theonymfi Tavladaki; Anna Maria Spanaki; Eumorfia Kondili; Helen Dimitriou; Sotirios Tsiodras; Dimitrios Georgopoulos; Apostolos Armaganidis; George Daikos; George Briassoulis
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 6.  Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids.

Authors:  Tom Vanden Berghe; Eric Hoste
Journal:  Cell Death Differ       Date:  2018-09-10       Impact factor: 15.828

7.  Serum caspase-cleaved cytokeratin-18 fragment as a prognostic biomarker in hematological patients with febrile neutropenia.

Authors:  Carina Intke; Sini Korpelainen; Marika Lappalainen; Matti Vänskä; Sari Hämäläinen; Kari Pulkki; Esa Jantunen; Auni Juutilainen; Anna-Kaisa Purhonen
Journal:  Clin Exp Med       Date:  2021-07-13       Impact factor: 3.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.